Eisai at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Eisai takes part in 5 sessions at CTAD 2026 in Boston. Its program centres on lecanemab, from CSF proteomics to residual biomarker effects after treatment stops. Its work also covers blood-based biomarker tests and the time it takes patients to start anti-amyloid therapy.

Organization	CTAD 2026 Attendance
Eisai Tokyo, Japan	◆Platinum Sponsor
eisai.com Large pharmaPlatinum Sponsor Japanese drugmaker that co-developed and markets lecanemab (Leqembi), an anti-amyloid antibody for early Alzheimer's disease, with Biogen.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Beyond Amyloid Clearance: CSF Proteomics Reveals Proteome-Wide CNS Remodeling Following Lecanemab Treatment (P007) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Impact of Blood-Based Biomarkers (BBMs) on Time to Treatment Initiation with Anti-Amyloid Therapies (AATs): A Retrospective Analysis Using the Optum Market Clarity Alzheimer’s Enriched Data (P248) Blood and CSF biomarkers · Real-world data and access Poster Wed Nov 18 7:15am–5:30pm Preferences and access considerations for clinical adoption of blood-based biomarker tests to confirm amyloid-β pathology in early Alzheimer’s disease: a 12-country survey (P294) Real-world data and access · Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab (P319) Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Talk Thu Nov 19 1:35pm Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Organization

CTAD 2026 Attendance

Eisai

Tokyo, Japan

◆Platinum Sponsor

eisai.com

Large pharmaPlatinum Sponsor

Japanese drugmaker that co-developed and markets lecanemab (Leqembi), an anti-amyloid antibody for early Alzheimer's disease, with Biogen.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Beyond Amyloid Clearance: CSF Proteomics Reveals Proteome-Wide CNS Remodeling Following Lecanemab Treatment (P007)

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Poster

Wed Nov 18
7:15am–5:30pm

Impact of Blood-Based Biomarkers (BBMs) on Time to Treatment Initiation with Anti-Amyloid Therapies (AATs): A Retrospective Analysis Using the Optum Market Clarity Alzheimer’s Enriched Data (P248)

Blood and CSF biomarkers · Real-world data and access

Poster

Wed Nov 18
7:15am–5:30pm

Preferences and access considerations for clinical adoption of blood-based biomarker tests to confirm amyloid-β pathology in early Alzheimer’s disease: a 12-country survey (P294)

Real-world data and access · Blood and CSF biomarkers

Poster

Wed Nov 18
7:15am–5:30pm

Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab (P319)

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Talk

Thu Nov 19
1:35pm

Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Instantly find 20 buyers from Eisai

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction